tiotropium low dose

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02242266

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2005-07-28Updated: 2023-12-01

Phase 3

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

CompletedNCT01277523

Boehringer IngelheimAsthma

Start: 2011-01-31End: 2013-10-31Updated: 2014-10-20

Related Papers

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>.

2019-07-1817 citations

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

P45 Effect of tiotropium respimat® on seasonal asthma worsening in paediatric patients

2018-11-161 citations

P155 Safety of tiotropium respimat® add-on therapy in patients aged 6–17 years with symptomatic asthma

Thorax2016-11-151 citations

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

European Respiratory Journal2016-11-03106 citations

Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma

2016-09-011 citations

Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma

2016-09-01